Compare DEI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | TSHA |
|---|---|---|
| Founded | 1971 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2006 | 2020 |
| Metric | DEI | TSHA |
|---|---|---|
| Price | $9.50 | $4.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $12.94 | $11.11 |
| AVG Volume (30 Days) | 2.1M | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 8.07% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,003,982,000.00 | $9,773,000.00 |
| Revenue This Year | $2.29 | N/A |
| Revenue Next Year | $2.04 | $1,228.40 |
| P/E Ratio | $104.56 | ★ N/A |
| Revenue Growth | 1.77 | ★ 17.28 |
| 52 Week Low | $9.04 | $1.13 |
| 52 Week High | $16.94 | $6.02 |
| Indicator | DEI | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 50.83 |
| Support Level | $9.41 | $4.33 |
| Resistance Level | $10.18 | $5.31 |
| Average True Range (ATR) | 0.30 | 0.27 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 57.69 | 67.38 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.